🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application
ATMA Journey Centers Inc. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, is pleased to announce it has submitted an N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA) to Health Canada, which aims …
ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada Read More »
As psychedelic therapy regulations are being implemented, drafted and discussed globally, the need to educate doctors, psychiatrists and prescribers in psychedelics is greater than ever.
First-of-its-kind clinical trial establishes the Company’s drug pipeline and strategic plan to supply thousands of therapists VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) …
In response to Australia’s approval of MDMA and psilocybin use in therapy AUSTRALIA, Feb. 7, 2023 /PRNewswire/ — ATMA Journey Centers Inc. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, is pleased to offer its psychedelic therapy training programs …
CALGARY, ALBERTA, CANADA, February 3, 2023 /EINPresswire.com/ — ATMA Journey Centers Inc. (“ATMA”), a Canada’s leading psychedelic-assisted therapy training provider, is pleased to announce their intent to form an affiliate partnership …
ATMA AND LINDEN MEDICAL CENTRE TO BECOME AFFILIATE PARTNERS Read More »
CALGARY, ALBERTA, CANADA, January 25, 2023 /EINPresswire.com/ — In response to the new Alberta Regulations on psychedelic assisted therapy, ATMA Journey Centers Inc. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, has announced …
CALGARY, ALBERTA, CANADA, January 18, 2023 /EINPresswire.com/ — ATMA Journey Centers Inc. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, is pleased to announce it will be offering the first psychedelic training …
ATMA Offers the First Psychedelic Training Program for Physicians and Prescribers Read More »
KINGSTON, ONTARIO, CANADA, January 5, 2023 /EINPresswire.com/ — ATMA Journey Centers Inc. (“ATMA”), a Canada’s leading psychedelic-assisted therapy training providers, is pleased to announce their affiliate partnership with Neuma Centre, Kingston’s first …
VANCOUVER, BRITISH COLUMBIA, CANADA, December 8, 2022 /EINPresswire.com/ — ATMA Journey Centers Inc. (“ATMA”), a Canadian-based company focused on the providing international psychedelic-assisted therapy training and support for mental healthcare professionals, …
ATMA and QI Integrated Health to Become Affiliate Partners Read More »
ATMA’s N500 Phase II Clinical Trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB, Sept. 14, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company …
Copyright © 2023 ATMA
